Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.

Interferon-α (IFNα) has been prescribed to effectively treat multiple myeloma (MM) and other malignancies for decades. Its use has waned in recent years, however, due to significant toxicity and a narrow therapeutic index (TI). We sought to improve IFNα's TI by, first, attaching it to an anti-C...

Full description

Bibliographic Details
Main Authors: Sarah L Pogue, Tetsuya Taura, Mingying Bi, Yong Yun, Angela Sho, Glen Mikesell, Collette Behrens, Maya Sokolovsky, Hussein Hallak, Moti Rosenstock, Eric Sanchez, Haiming Chen, James Berenson, Anthony Doyle, Steffen Nock, David S Wilson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5017640?pdf=render

Internet

http://europepmc.org/articles/PMC5017640?pdf=render

Similar Items